Human papillomavirus (HPV) can infect men and women through close skin and mucosal contact. Low-risk types are often linked with genital warts. If a high-risk type persists, it is linked with some cancers of the cervix, vulva, vagina, anus, penis and oropharynx.
The 9-valent vaccine covers nine types and is used to lower the chance of acquiring types a person does not already have. It does not clear an existing infection and does not treat warts that are already present. Whether to vaccinate, how many doses, and follow-up should be decided with a urologist.
Key points: HPV can infect men and women. Types 6 and 11 are the types usually linked with genital warts. Types such as 16 and 18, if they persist, are linked with some cancers. The 9-valent vaccine covers nine types. It lowers risk for types not yet acquired. It does not clear existing virus and does not treat warts that are already there. A clinician should advise on vaccination.
What is human papillomavirus (HPV)?
HPV is a DNA virus that infects skin and mucosa. Men and women can both be infected, and many people have no clear symptoms.
The usual route is close skin and mucosal contact, including vaginal, anal and oral sex. The chance of infection usually rises after sexual activity begins. Risk may be higher when immunity is weaker or protection is inconsistent.
Hot springs and public baths are not the route public-health guidance emphasizes. Protection during intimate contact, and seeing a clinician if a lesion appears, matter more.
Some public-health materials say that sexually active people have a substantial lifetime chance of encountering HPV, sometimes described as about eight in ten. Estimates differ between studies, and contact with the virus does not mean a person will become ill.
HPV is a different virus from HIV. Medicine used to reduce HIV risk is discussed separately in HIV preventive medication (PrEP and PEP). That page cannot replace testing or an in-person assessment.
How do high-risk and low-risk types differ?
Many HPV types are known. They are often grouped as low-risk or high-risk, and the problems linked with them are not the same. Infection with one type does not protect against the others.
The immune system clears many infections, so an infection does not always leave a lasting problem. A high-risk type is linked with some cancers and precancerous changes only if it persists. Infection itself is not a cancer diagnosis.
Some studies in Asian populations have observed that types 52 and 58 are relatively common, which is why the 9-valent vaccine includes them. The actual type cannot be guessed from symptoms.
| Group | Common types | Problems that may be related | Limit to keep in mind |
|---|---|---|---|
| Low-risk | Types 6 and 11 | Genital warts | Usually not cancer-causing; lesions can return after treatment |
| High-risk | Types 16, 18, 31, 33, 45, 52, 58 and others | Some cancers and precancerous changes of the cervix, vulva, vagina, anus, penis and oropharynx | Infection is not a cancer diagnosis; many infections clear |
How are genital warts related to HPV?
Genital warts are caused mainly by low-risk types 6 and 11. They are lesions of the skin and mucosa and are usually not cancer.
Warts, flat bumps and other growths can look alike. A clinician needs to examine them. Comparing photos at home is not a diagnosis.
After a visible lesion is treated, virus may remain in nearby tissue, so another lesion can appear later. Options include topical medicine, freezing, electrocautery, laser or excision. The clinician chooses according to site, number, extent and general health. No single method suits every person.
A study of unvaccinated men aged 18 to 70 in Brazil, Mexico and the United States observed that about four in ten had a later wart episode after the first. That result does not apply to every patient and does not mean surgery is required.
The vaccine does not remove warts that are already present. Studies do not agree on whether vaccination lowers the chance of warts returning after treatment. It should not be used as a treatment.
Why is the 9-valent vaccine called a wart vaccine?
“Wart vaccine” is an informal name for the 9-valent HPV vaccine, because types 6 and 11, which are linked with genital warts, are included. The same vaccine also covers several high-risk types, so the discussion is not limited to warts.
The nine types are 6, 11, 16, 18, 31, 33, 45, 52 and 58. The vaccine does not cover every HPV type.
In some trials, people who had not yet acquired the matching types had clear protection against lesions linked with those types. The vaccine cannot clear a type that is already present, and protection is not the same for every person.
The U.S. Food and Drug Administration has authorized the 9-valent vaccine to prevent some head and neck cancers related to vaccine types. That authorization does not cover every head and neck cancer. Eligibility still depends on the current approval and a clinician’s assessment.
Men and women can both discuss vaccination. It is usually deferred during pregnancy. Tell the clinician if you are pregnant, planning pregnancy, or have weaker immunity. The number and spacing of doses follow age and the current product guidance.
Soreness or redness at the injection site is common. Some people have a headache or a mild fever. Sit and rest for a short time after the injection. Trouble breathing or a widespread rash needs urgent care.
Do men need the HPV vaccine?
Men can be infected too. Infection often causes no symptoms, and there is no routine screening test equivalent to a cervical smear, so a person may pass the virus to a partner without knowing.
Some U.S. epidemiology from 2013–2014 observed a genital HPV prevalence of about 45% among adult men. That figure belongs to that time and place. It is not the infection rate for every man in Taiwan.
Persistent high-risk infection is linked with some cancers of the penis, anus and oropharynx, but infection is not a cancer diagnosis. Age, sexual history, past doses and general health should be discussed with a clinician before vaccination.
Can someone who already has HPV still be vaccinated?
This can be discussed, with the right expectation. The vaccine does not treat the current type and does not make existing warts disappear.
Because there are many types, infection with one type does not rule out others. Vaccination may still protect against types not yet acquired. If a lesion is already present, it should be assessed and treated before the timing of vaccination is decided.
A new partner, or a wish to lower the chance of later types, is a reasonable reason to raise the question in clinic. The decision depends on the individual.
How is HPV prevented, and when should someone seek care?
Several steps can be used together: condoms for the whole encounter, a discussion about the vaccine, and cervical screening for women according to current advice. A condom lowers risk, but skin and mucosa outside the condom can still touch the virus.
Men do not have an equivalent routine smear. A new bump, bleeding, pain, unusual discharge, or discomfort passing urine, on the genitals, anus or mouth, should be examined rather than watched at home.
If a partner is diagnosed with warts or an HPV-related lesion, both people are suitable for assessment. Ask a clinician about intimate contact before the lesion has been examined.
Women usually still need screening after vaccination, at the interval advised for their age. The vaccine does not cover every type. Screening looks for cell changes. The two steps have different roles.
Which questions about HPV and the wart vaccine come up often?
These are questions often asked in clinic and in search. Whether vaccination is suitable, and whether a lesion needs treatment, still require an in-person urology assessment.
No. The 9-valent vaccine lowers the chance of types not yet acquired. It cannot clear existing virus or remove warts that are already there. A clinician chooses medicine, freezing or another method. Lesions can still return.
Yes. HPV spreads by close skin and mucosal contact. Fewer partners does not mean there is no chance. Feeling well does not show whether infection is present. A lesion or uncertain symptom should be examined.
Correct use throughout sex lowers risk, but it does not block every contact, because skin outside the condom can still touch the virus. Condoms can be combined with a vaccine discussion and screening. They do not replace a clinical visit.
Usually yes. The vaccine does not cover every HPV type. A smear and related tests look for cell changes on the cervix. Age and interval follow current advice. Vaccination is not a reason to stop screening on one’s own.
The vaccine still cannot treat that lesion. Because other types exist, a clinician may still discuss vaccination to lower the chance of types not yet acquired. Whether and when to vaccinate depends on treatment progress and the individual.
The clearer route is close skin and mucosal contact, not bathing. Shared towels and public baths are not the main route. A new bump, bleeding or discomfort on the genitals or anus should still be assessed in person.
Suggestions from the urologist
- HPV can infect men and women. Low-risk types are mainly linked with genital warts. A high-risk type is linked with some cancers only if it persists. Infection itself is not a cancer diagnosis.
- The 9-valent vaccine lowers risk for types not yet acquired. It does not clear virus that is already present and cannot be used to treat warts that are already there.
- A condom used for the whole encounter lowers risk, but uncovered skin can still touch the virus. A new bump, bleeding, pain, or a partner’s diagnosis should be examined.
- Doses, pregnancy, immunity, and how to treat a lesion all need an individual urology assessment.
The useful distinction is which HPV types are involved, what the vaccine can prevent, and that warts still need clinical care. The vaccine is not a treatment, and protection differs between people. Discuss vaccination, or any uncertain lesion on the genitals or anus, with a urologist.
